Spotify Q2 Gross Margin Rises to 33.4%, But Key Demand and Ad Revenue Catalysts Remain Unconfirmed

What happened

Spotify's Q2 gross margin expanded to 33.4%, up from 33% in Q1, as Premium revenue growth outpaced music costs and Ad-Supported segment profitability improved. The company's strategy of repricing Premium and shifting ads toward automated channels appears to be bearing fruit on the margin front. However, the Zacks article does not confirm whether Premium subscribers met the 299 million guide for Q2, nor whether Ad-Supported revenue returned to year-over-year growth, both critical catalysts identified in our prior analysis. These missing details leave the margin improvement insufficient to de-risk the thesis, especially given the stock's premium valuation. The market will likely focus on subscriber retention post-price-hike and ad pricing stabilization in the full earnings release before reassessing the investment case.

Implication

The gross margin expansion is a positive signal that Spotify's profitability narrative is intact, but it does not address the two pivotal uncertainties: post-price-hike subscriber churn and ad monetization rebound. Without confirmation of ≥299M Premium subscribers and a return to Ad-Supported revenue growth, the stock's 26.8x P/E leaves limited room for disappointment. Investors should wait for the full Q2 earnings release, which will reveal demand elasticity and ad yield trends. Any shortfall in these metrics could trigger a sharp de-rating, while a beat could justify a re-rating. Given the current valuation, risk-reward remains balanced against buying, supporting a WAIT stance with a re-assessment window of three to six months.

Thesis delta

The news partially de-risks the margin expansion component of our thesis, as Q2 gross margin hit 33.4% and Ad-Supported profitability improved. However, the two primary catalysts for upgrading—Premium subscribers meeting the 299M guide and Ad-Supported revenue returning to YoY growth—are not confirmed by this summary. Therefore, our WAIT rating remains appropriate, with a slight upward bias if subsequent disclosures confirm both catalysts.